FDA Clears Patient Controller Platform for Stimwave’s Neuromodulation Device

The Food and Drug Administration has cleared the WaveCrest Mobile iOS Platform for patients with Stimwave’s Wireless Freedom Spinal Cord Stimulator (SCS) System, allowing them to control their pain relief therapy through an iPhone or Apple Watch. 

The Stimwave SCS System utilizes a tiny injectable microchip device that sends small pulses of energy to electrodes near surrounding nerves. This elicits a reaction that allows the remapping of specific pain signals, thus resulting in pain relief. The device is implanted under the skin in an outpatient procedure. “The Freedom System not only is the smallest option available for patients eliminating the complexities of an implanted lithium ion battery, but offers a wide variety of advanced programming features that the patient can choose through their mobile device,” said Dr. Ellen Lin, MD, medical director of San Antonio’s Advanced Spine and Pain Center.

The new software enables patients to fine-tune the power level and modify programs that were pre-programmed by their clinician to control pain. 

For more information visit Stimwave.com.